AstraZeneca’s Phase 3 Farxiga data impresses in type 2 diabetes
pharmafile | June 11, 2019 | News story | Manufacturing and Production, Research and Development | AstraZeneca, diabetes, farxiga, pharma, type 2 diabetes
AstraZeneca has presented new Phase 3 data at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco on its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin), demonstrating that the drug successfully reduced the progression of kidney disease or renal death in patients with type 2 diabetes (T2D).
Derived from 17,160 T2D patients with predominantly reserved renal function irrespective of underlying atherosclerotic CV disease (ASCVD), the data revealed that Farxiga reduced the relative risk of the composite renal-specific outcome of kidney function decline, end-stage renal disease and renal death by 47% compared to placebo.
Additionally, the drug also reduced the relative risk of a cardio-renal composite of kidney function decline, ESRD, or renal or cardiovascular (CV) death by 24% compared to placebo, and demonstrated a lower incidence of ESRD compared to placebo.
“Heart failure and renal diseases are two of the most common and early complications experienced by people living with type-2 diabetes, and are too often overlooked,” commented AZ’s Elisabeth Björk, Senior Vice President, Head of Late-stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D. “They contribute to a growing economic burden on the global healthcare system and can lead to fatal outcomes for patients. These data continue to offer clinically relevant evidence of the early cardio-renal effects of Farxiga.”
Matt Fellows
Related Content
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …
NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …
